면역치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Immunotherapy Drugs Market size is expected to reach USD 345.58 Billion in 2034 from USD 180.40 Billion (2025) growing at a CAGR of 7.49% during 2026-2034.

The Global Immunotherapy Drugs market has experienced rapid expansion due to growing prevalence of cancer and autoimmune diseases. Immunotherapy harnesses the body's immune system to fight disease, offering targeted and durable treatment outcomes. Increasing approval of checkpoint inhibitors and monoclonal antibodies has significantly strengthened market growth. Rising healthcare expenditure and improved diagnostic capabilities further support widespread adoption across developed and emerging regions.

Key growth drivers include advancements in biologics research and personalized medicine approaches. Pharmaceutical companies are investing heavily in clinical trials to expand indications for existing therapies. Combination treatments integrating immunotherapy with chemotherapy or radiation are gaining momentum. Additionally, supportive regulatory frameworks and fast-track approvals accelerate product commercialization.

Future prospects remain highly promising as innovation in cell-based therapies and cancer vaccines advances. Expanding applications in infectious and chronic diseases will broaden the market scope. Improved accessibility in developing economies will further stimulate demand. The immunotherapy drugs market is expected to maintain strong long-term growth driven by scientific breakthroughs.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• Monoclonal Antibodies
• Immunomodulators
• Cell Therapy
• Others (Vaccines, etc.)

By Therapy Area

• Cancer
• Autoimmune Diseases
• Infectious Diseases
• Others

By Distribution Channel

• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies

COMPANIES PROFILED

• Bristol Myers Squibb, Merck Co Inc, F HoffmannLa Roche AG, Novartis AG, AstraZeneca, Pfizer Inc, Amgen Inc, Gilead Sciences, Regeneron Pharmaceuticals Inc, Eli Lilly and Company
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL IMMUNOTHERAPY DRUGS MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Immunomodulators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others (Vaccines, etc.) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL IMMUNOTHERAPY DRUGS MARKET: BY THERAPY AREA 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapy Area
• 5.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Autoimmune Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL IMMUNOTHERAPY DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL IMMUNOTHERAPY DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Type
  • 7.2.2 By Therapy Area
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Type
  • 7.3.2 By Therapy Area
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Type
  • 7.4.2 By Therapy Area
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Type
  • 7.5.2 By Therapy Area
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Type
  • 7.6.2 By Therapy Area
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL IMMUNOTHERAPY DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Bristol Myers Squibb
  • 9.2.2 Merck & Co. Inc
  • 9.2.3 F. Hoffmann-La Roche AG
  • 9.2.4 Novartis AG
  • 9.2.5 AstraZeneca
  • 9.2.6 Pfizer Inc
  • 9.2.7 Amgen Inc
  • 9.2.8 Gilead Sciences
  • 9.2.9 Regeneron Pharmaceuticals Inc
  • 9.2.10 Eli Lilly And Company